GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » CytoSorbents Corp (STU:HQE1) » Definitions » Cyclically Adjusted Price-to-FCF

CytoSorbents (STU:HQE1) Cyclically Adjusted Price-to-FCF : (As of Jun. 09, 2024)


View and export this data going back to 2011. Start your Free Trial

What is CytoSorbents Cyclically Adjusted Price-to-FCF?

Shiller PE for Stocks: The True Measure of Stock Valuation


CytoSorbents Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for CytoSorbents's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CytoSorbents Cyclically Adjusted Price-to-FCF Chart

CytoSorbents Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

CytoSorbents Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of CytoSorbents's Cyclically Adjusted Price-to-FCF

For the Medical Devices subindustry, CytoSorbents's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


CytoSorbents's Cyclically Adjusted Price-to-FCF Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, CytoSorbents's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where CytoSorbents's Cyclically Adjusted Price-to-FCF falls into.



CytoSorbents Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

CytoSorbents's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, CytoSorbents's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2024 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=-0.084/131.7762*131.7762
=-0.084

Current CPI (Mar. 2024) = 131.7762.

CytoSorbents Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201406 -0.095 100.560 -0.124
201409 -0.124 100.428 -0.163
201412 -0.079 99.070 -0.105
201503 -0.080 99.621 -0.106
201506 -0.083 100.684 -0.109
201509 -0.087 100.392 -0.114
201512 -0.089 99.792 -0.118
201603 -0.048 100.470 -0.063
201606 -0.074 101.688 -0.096
201609 -0.093 101.861 -0.120
201612 -0.044 101.863 -0.057
201703 -0.080 102.862 -0.102
201706 -0.071 103.349 -0.091
201709 -0.081 104.136 -0.102
201712 -0.029 104.011 -0.037
201803 -0.074 105.290 -0.093
201806 -0.106 106.317 -0.131
201809 -0.080 106.507 -0.099
201812 -0.084 105.998 -0.104
201903 -0.131 107.251 -0.161
201906 -0.096 108.070 -0.117
201909 -0.155 108.329 -0.189
201912 -0.126 108.420 -0.153
202003 -0.099 108.902 -0.120
202006 0.035 108.767 0.042
202009 -0.075 109.815 -0.090
202012 -0.025 109.897 -0.030
202103 -0.057 111.754 -0.067
202106 -0.058 114.631 -0.067
202109 -0.101 115.734 -0.115
202112 -0.146 117.630 -0.164
202203 -0.187 121.301 -0.203
202206 -0.276 125.017 -0.291
202209 -0.173 125.227 -0.182
202212 -0.120 125.222 -0.126
202303 -0.081 127.348 -0.084
202306 -0.142 128.729 -0.145
202309 -0.115 129.860 -0.117
202312 -0.129 129.419 -0.131
202403 -0.084 131.776 -0.084

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


CytoSorbents  (STU:HQE1) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


CytoSorbents Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of CytoSorbents's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


CytoSorbents (STU:HQE1) Business Description

Traded in Other Exchanges
Address
305 College Road East, Princeton, NJ, USA, 08540
CytoSorbents Corp is involves in the treatment of life-threatening conditions in the intensive care (ICU) and cardiac surgery using blood purification via proprietary polymer adsorption technology. It has a number of products commercialized and in development based on this technology platform.

CytoSorbents (STU:HQE1) Headlines

No Headlines